Save Product
Product Details
Synonyms
TGFB2, MGC116892, TGFβ2, TGF-beta2
Source
Human TGF-Beta 2, Tag Free (TG2-H4215) is expressed from human 293 cells (HEK293). It contains AA Ala 303 - Ser 414 (Accession # P61812-1).
Predicted N-terminus: Ala 303
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 12.7 kDa. The protein migrates as 23-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in TFA and ACN with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human TGF-Beta 2, Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-BLI
Loaded Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) on Protein A Biosensor, can bind Human TGF-Beta 2, Tag Free (Cat. No. TG2-H4215) with an affinity constant of 8.09 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Transforming growth factor beta 2
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
6 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
